HTBX Heat Biologics Inc

Rosen Law Firm Closes Investigation and Concludes There is No Basis for Securities Claims Against HTBX

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm announces that, following discussions with management and having gained a better understanding of the facts surrounding Heat Biologic’s (NASDAQ:HTBX) recent bladder cancer trial for Vesigenurtacel-L (HS-410), including the positive immunological data generated from this trial, it is closing its investigation of HTBX. Rosen attorney Phil Kim stated “We have concluded that there is no suggestion that management misrepresented the results of the clinical trial, and there is no basis for any securities claims.”

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
01/12/2016

Underlying

HTBXHeat Biologics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Heat Biologics Inc

 PRESS RELEASE
Free
HTBX Heat Biologics ...

Heat Biologics Announces Planned Transfer to the NYSE American

Heat Biologics Announces Planned Transfer to the NYSE American DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it plans to change its listing from the Nasdaq Capital Market to the NYSE American stock exchange. “We are pleased to announce our listing on the NYSE American, a global leader in listings for a range of sectors, including life sciences and technology,” said Jeff Wolf, Chairman and Chief Execut...

February 2, 2022 1 EN
 PRESS RELEASE
Free
HTBX Heat Biologics ...

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Tre...

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S. government’s strategy to maintain sufficient quantities of anthrax anti-toxin to effectively respond to an anthrax emergency PARSIPPANY, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Elusys Therapeutics, Inc. (Elusys) announced today that it has ...

January 31, 2022 1 EN
 PRESS RELEASE
Free
HTBX Heat Biologics ...

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transpla...

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110 Data demonstrates that PTX-35 may have utility in solid organ transplantation, and to potentially slow or mitigate deleterious immune responses where self-tissue tolerance is impaired DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclinical data regarding PTX-35 has been accepted for ...

January 12, 2022 1 EN
 PRESS RELEASE
Free
HTBX Heat Biologics ...

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM® (obiltoxaximab) Injection, ...

December 21, 2021 1 EN
 PRESS RELEASE
Free
HTBX Heat Biologics ...

Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Ta...

Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a rapid, safe, and effective response to potential biological threats RapidVax Presentation at the 2021 World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress 2021 DURHAM, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NAS...

November 30, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch